CMS created three new MS-DRGs whose relative weights will be calibrated to account for hemodialysis costs and will therefore be excluded from additional ESRD payments.
A version of this article was first published September 29, 2020, by HCPro's Revenue Cycle Advisor, a sibling publication to HealthLeaders.
Q: What changes to inpatient dialysis MS-DRGs did CMS finalize in the fiscal year 2021 Inpatient Prospective Payment System final rule?
A: CMS made several changes to reimbursement for inpatient dialysis.
Medicare will continue to pay an additional amount to hospitals for stays during which end-stage renal disease (ESRD) beneficiaries receive dialysis treatment, as long as ESRD beneficiary discharges constitute 10% or more of total Medicare discharges.
However, CMS created three new MS-DRGs whose relative weights will be calibrated to account for hemodialysis costs and will therefore be excluded from additional ESRD payments:
- MS-DRG 019 (Simultaneous Pancreas/Kidney Transplant with Hemodialysis)
- MS-DRG 650 (Kidney Transplant with Hemodialysis with MCC)
- MS-DRG 651 (Kidney Transplant with Hemodialysis without MCC)
CMS is also removing MS-DRGs 652 and 685 from the list of MS-DRGs excluded from additional ESRD payments.
For more informaiton, see "Note from the instructor: FY 2021 IPPS payment factors and related adjustments," by Judith L. Kares, JD.
Revenue Cycle Advisor combines all of HCPro's Medicare regulatory and reimbursement resources into one handy and easy-to-access portal. News is not just repeated from other sources. It is analyzed by our Medicare experts so professionals can comprehend any new rule and regulatory updates thoroughly. Learn more.